EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Co-Diagnostics's enterprise value is $-17.73 Mil.
Co-Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $6.81 Mil. Therefore, Co-Diagnostics's EV-to-Revenue for today is -2.60.
The historical rank and industry rank for Co-Diagnostics's EV-to-Revenue or its related term are showing as below:
CODX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -6.41 Med: 6.32 Max: 7105.25
Current: -2.6
During the past 9 years, the highest EV-to-Revenue of Co-Diagnostics was 7105.25. The lowest was -6.41. And the median was 6.32.
CODX's EV-to-Revenue is ranked better than 98.79% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 3.22
vs CODX: -2.60
As of today (2024-05-04), Co-Diagnostics's stock price is $1.21.
Co-Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.23. Therefore, Co-Diagnostics's PS Ratio for today is 5.22.
Co-Diagnostics EV-to-Revenue Historical Data
The historical data trend for Co-Diagnostics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Co-Diagnostics's EV-to-Revenue
For the Medical Devices subindustry, Co-Diagnostics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's EV-to-Revenue falls into.
Co-Diagnostics's current Enterprise Value is $-17.73 Mil.
Co-Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics's share price for today is $1.21.
Co-Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Co-Diagnostics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Co-Diagnostics (Co-Diagnostics) Business Description
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CODX has been successfully added to your 